Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor

Pediatric Infectious Disease Journal

Volumn 21, Issue 3, 2002, Pages 214-220

  Servais, Jean ^a   Hainaut, Marc ^b   Schmitz, Véronique ^d   Maes, Philip ^f   Fransen, Katrien ^g   Vaira, Dolores ^e   Brichard, Bénédicte ^c   Arendt, Vic ^a   Schneider, François ^a   Hemmer, Robert ^a   Schmit, Jean Claude ^a  

^a Retrovirology Laboratory Luxembourg   (Luxembourg)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f MIDDELHEIM HOSPITAL   (Belgium)

^g INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Cross resistance; Highly active antiretroviral therapy; Human immunodeficiency virus type 1 infected children; Nelfinavir; Protease inhibitor resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; FOSCARNET; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CROSS RESISTANCE; DRUG CHOICE; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVE SITE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; INFECTION SENSITIVITY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVERSE TRANSCRIPTION; SALVAGE THERAPY; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS MUTATION; WILD TYPE;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TREATMENT FAILURE;

EID: 0036119126     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200203000-00011     Document Type: Article

References (22)

1. Variable use of therapeutic interventions for children wit human immunodeficiency virus type 1 infection in Europe
2. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1 infected children
3. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: A randomized controlled trial
4. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomized controlled trial-PACTG 377
5. Comparison of ritonavir plus saquinavirand nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection
6. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV cohort study
7. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
8. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
9. HIV genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
10. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
11. Revised classification system for human immunodeficiency virus infection in children <13 years of age
12. Antiretroviral drug resistance testing in adult HIV-1 infection, recommendations of an International AIDS Society - USA panel
13. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs
14. The median-effect principle and the combination index for quantitation of synergism and antagonism
15. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
16. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
17. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads: A prospective, randomized, multicenter, open-label study (DMP 049)
18. Mutation pattern of the RT and protease genes in HIV-infected children receiving combination therapy
19. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 in patients failing highly active antiretroviral therapy
20. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
21. Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor
22. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate